Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity

Cancer

Volumn 79, Issue 6, 1997, Pages 1180-1189

  Mizutani, Youichi ^a   Okada, Yusaku ^a   Yoshida, Osamu ^a   Fukumoto, Manabu ^a   Bonavida, Benjamin ^b  

^a KYOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

apoptosis; bladder carcinoma; doxorubicin; Fas; synergy

Indexed keywords

DOXORUBICIN; EPIRUBICIN; FAS ANTIGEN; FLUOROURACIL; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; MESSENGER RNA; METHOTREXATE; MITOMYCIN C; MONOCLONAL ANTIBODY; PIRARUBICIN;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOMA; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CARCINOMA CELL; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; NORTHERN BLOTTING; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD95; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; DOXORUBICIN; DRUG RESISTANCE; DRUG SYNERGISM; FLOW CYTOMETRY; HUMANS; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 0030893933     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970315)79:6<1180::AID-CNCR17>3.0.CO;2-W     Document Type: Article

References (44)

1. Safrit JT, Bonavida B. Hierarchy of sensitivity and resistance of tumor cells to cytotoxic effector cells, cytokines, drugs, and toxins. Cancer Immunol Immunother 1992;34:321-8.
2. Bonavida B, Tsuchitani T, Safrit JT, Zighelboim J. Hierarchy of tumor cell sensitivity and resistance to cytolysis by TNF, cytotoxic cells, bacterial toxins, and cytotoxic drugs. In: Bonavida B, Granger G. Tumor necrosis factor: structure, mechanism of action, role in disease and therapy. Basel: Karger, 1990:125-32.
3. Birkhead BG. Evaluating and designing cancer chemotherapy treatment using mathematical models. Eur J Cancer Clin Oncol 1986;22:3-8.
4. Mizutani Y, Bonavida B. Overcoming CDDP resistance of human ovarian tumor cells by combination treatment with CDDP and TNF-α. Cancer 1993;72:809-18.
5. Safrit JT, Bonavida B. Sensitivity of resistant human tumor cell lines to tumor necrosis factor and Adriamycin used in combination: correlation between down-regulation of tumor necrosis factor-messenger RNA induction and over-coming resistance. Cancer Res 1992;52:6630-7.
6. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265:528-30.
7. Arase H, Arase N, Saito T. Fas-mediated cytotoxicity by freshly isolated natural killer cells. J Exp Med 1995;181:1235-8.
8. Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/ nerve growth factor receptor superfamily: sequence identity with the Fas antigen. J Biol Chem 1992;267:10709-15.
9. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima SI, Sameshima M, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66:233-43.
10. Watanabe-Fukunaga R, Brannan CI, Itoh N, Yonehara S, Copeland NG, Jenkins NA, et al. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 1992;148:1274-9.
11. Nagata S. Fas and Fas ligand: a death factor and its receptor. Adv Immunol 1994;57:129-44.
12. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-78.
13. Smith CA, Farrah T, Goodwin RG. The TNF receptor super-family of cellular and viral proteins: activation, costimulation, and death. Cell 1994;76:959-62.
14. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993;364:806-9.
15. Trauth BC, Klas C, Peters AMJ, Matzuku S, Moller P, Falk W, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989;245:301-5.
16. Mizutani Y, Nio Y, Fukumoto M, Yoshida O. Effects of bacillus Calmette-Guerin on cytotoxic activities of peripheral blood lymphocytes against human T24 lined and freshly isolated autologous urinary bladder transitional carcinoma cells in patients with urinary bladder cancer. Cancer 1992; 69:537-45.
17. Mizutani Y, Okada Y, Terachi T, Kakehi Y, Yoshida O. Serum granulocyte colony-stimulating factor levels in patients with urinary bladder tumour and various urological malignancies. Br J Urol 1995;76:580-6.
18. Mizutani Y, Okada Y, Terachi T, Yoshida O. Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with urinary bladder cancer. J Urol 1996;155:888-94.
19. Mizutani Y, Nio Y, Yoshida O. The streptococcal preparation OK-432 specifically augments the susceptibility of human urinary bladder tumor cells to the autologous peripheral blood lymphocytes. Cancer 1992;69:2999-3007.
20. Mizutani Y, Yoshida O. Overcoming TNF-α resistance of human renal and ovarian carcinoma cells by combination treatment with buthionine sulfoximine and TNF-α. Role of TNF-a mRNA downregulation in tumor cell sensitization. Cancer 1994;73:730-7.
21. Mizutani Y, Fukumoto M, Bonavida B, Yoshida O. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide. Cancer 1994;74:1546-54.
22. Murai N, Ueda T, Takahashi J, Yang H, Kikuchi H, Hatanaka M, et al. Apoptosis of human glioma cells in vitro and in vivo induced by a neutralizing antibody against human basic fibroblast growth factor. J Neurosurg. 1996;85:1072-7.
23. Shinozawa S, Mikami Y, Araki Y. Determination of the concentration of adriamycin and its metabolites in the serum and tissues of Ehrlich carcinoma-bearing mice by high-performance liquid chromatography. J Chromatogr 1980; 196:463-9.
24. Mizutani Y, Bonavida B, Koishihara Y, Akamatsu K, Ohsugi Y, Yoshida O. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum (II) by anti-interleukin-6 monoclonal antibody or anti-interleukin-6-receptor monoclonal antibody. Cancer Res 1995;55:590-6.
25. Mizutani Y, Bonavida B, Nio Y, Yoshida O. Overcoming TNF-α and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-α or drugs. J Urol 1994;151:1697-702.
26. Berenbaum MC. Synergy, additivism and antagonism in immunosuppression. Clin Exp Immunol 1977;28:1-18.
27. Berenbaum MC. A method for testing for synergy with any number of agents. J Infect Dis 1978;137:122-130.
28. Volm M, Mattern J, Samsel B. Relationship of inherent resistance to doxorubicin, proliferative activity and expression of P-glycoprotein 170, and glutathione S-transferase-π in human lung tumors. Cancer 1992;70:764-9.
29. Ahn H, Lee E, Kim K, Lee C. Effect of glutathione and its related enzymes on chemosensitivity of renal cell carcinoma and bladder carcinoma cell lines. J Urol 1994; 151:263-7.
30. Breuninger LM, Paul S, Gaughan K, Miki T, Chan A, Aaronson SA, et al. Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res 1995;55:5342-7.
31. Nooter K, Herweijer H. Multidrug resistance (MDR) genes in human cancer. Br J Cancer 1991;63:663-9.
32. Goldenberg GJ, Wang H, Blair GW. Resistance to Adriamycin: relationship of cytotoxicity to drug uptake and DNA single-and double-strand breakage in cloned cell lines of Adriamycin-sensitive and -resistant P388 leukemia. Cancer Res 1986;46:2978-83.
33. Deffie AM, Alam T, Senevirante C, Beenken SW, Batra JK, Shea TC, et al. Multifactorial resistance to Adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of Adriamycin-sensitive and -resistant P388 leukemia. Cancer Res 1988; 48:3595-602.
34. De Jong S, Zijlstra JG, De Vries EGE, Mulder NH. Reduced DNA topoisomerase II activity and drug-induced cleavage activity in an Adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 1990;50:304-9.
35. Deffie AM, Batra JK, Goldenberg GJ. Direct correlation between DNA topoisomerase II activity and cytotoxicity in Adriamycin-sensitive and resistant P388 leukemia cell lines. Cancer Res 1989;49:58-62.
36. Owen-Schaub LB, Radinsky R, Kruzel E, Berry K, Yonehara S. Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res 1994;54:1580-6.
37. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994;263:1759-62.
38. Itoh N, Tsujimoto Y, Nagata S. Effect of bcl-2 on Fas antigen-mediated cell death. J Immunol 1993;151:621-7.
39. Sentman CL, Shutter JR, Hockenberry D, Kanagawa O, Korsmeyer SJ. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 1991;67:879-88.
40. Sato T, Irie S, Kitada S, Reed JC. FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 1995;268:411-5.
41. Mori S, Mori K, Jewett A, Nakamura S, Bonavida B. Resistance of AIDS-associated Kaposi's sarcoma cells to Fas-mediated apoptosis. Cancer Res 1996;56:1874-9.
42. Kerr JFR, Winterford CM, Harmon BV. Apoptosis. Cancer 1994;73:2013-26.
43. Ohmori T, Podack ER, Nishio K, Takahashi M, Miyahara Y, Takeda Y, et al. Apoptosis of lung cancer cells caused by some anticancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem Biophys Res Comm 1993;192:30-6.
44. Shima Y, Nishio N, Ogata A, Fujii Y, Yoshizaki K, Kishimoto T. Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood 1995;85:757-64.